Molina Healthcare, INC

Molina Healthcare reported Q2 2026 results, with adjusted EPS of $1.51, and raised its full-year 2026 adjusted earnings guidance to at least $5.25 per diluted share.

Molina Healthcare has been selected by the Illinois Department of Healthcare and Family Services to provide managed care services under the HealthChoice Illinois program.

Molina Healthcare's 2026 Annual Meeting saw stockholders approve amendments to the 2025 Equity Incentive Plan and the Certificate of Incorporation, alongside director elections and executive compensation.

Molina Healthcare, Inc. announced its Investor Day Conference on May 8, 2026, where it will provide updates on its business, long-term financial targets, and strategic plans.

Molina Healthcare reported Q1 2026 adjusted EPS of $2.35 and reaffirmed its full-year 2026 adjusted earnings guidance of at least $5.00 per share.

Molina Healthcare, Inc. reaffirms its 2026 full-year GAAP diluted EPS guidance of at least $3.20 and adjusted diluted EPS guidance of at least $5.00 ahead of upcoming investor engagements.

Molina Healthcare's Q2 2026 results show a significant decrease in net income and membership compared to the prior year, driven by market contraction and strategic pricing adjustments.

Molina Healthcare reported a significant decrease in net income for Q1 2026, driven by lower membership across its Medicaid and Marketplace segments and a substantial impairment charge.

Molina Healthcare reported a significant decline in third-quarter net income and diluted EPS, primarily driven by a challenging medical cost trend environment across all segments.

Molina Healthcare's second quarter net income fell 15% year-over-year, driven by a challenging medical cost environment and higher Medical Care Ratios across all segments, despite strong revenue growth.

Molina Healthcare's Q1 2025 results show increased premium revenue and membership growth, offset by higher medical costs and strategic investments.

Molina Healthcare's Q3 2024 results show significant revenue growth and membership increases, while managing medical cost pressures and Medicaid redetermination impacts.

Molina Healthcare reports a significant decline in net income for 2025 despite robust revenue growth, driven by rising medical costs and strategic shifts in its government-sponsored healthcare segments.

Molina Healthcare's 2024 10-K filing reveals a year of profitable growth driven by Medicaid and Medicare programs, strategic acquisitions, and a focus on operational efficiency.

Molina Healthcare amends its 2011 Equity Incentive Plan into a new 2019 plan and files its 2023 annual report, highlighting financial performance and strategic growth.

Richard C. Zoretic, a Director at Molina Healthcare, Inc., was granted 237 shares of common stock on July 1, 2026, as part of his annual equity award.

Molina Healthcare reports a director, Richard M. Schapiro, received an equity award of 237 common stock shares valued at $55,000 on July 1, 2026.

Molina Healthcare, Inc. reports a stock grant to Director Ronna Romney under the company's equity incentive plan.

Steven J. Orlando, a Director at Molina Healthcare, Inc., was granted 237 shares of common stock valued at $55,000 as part of his annual equity award.

Molina Healthcare, Inc. reports a stock grant to Director Stephen H. Lockhart under the 2025 Equity Incentive Plan.

Molina Healthcare, Inc. reports a stock grant to Director Leo P. Grohowski under the 2025 Equity Incentive Plan.

Molina Healthcare's latest proxy statement reveals significant 2025 financial underperformance leading to no executive bonuses and forfeited equity awards, despite strong revenue growth and new contract wins.

Molina Healthcare, Inc. has filed a definitive proxy statement with the SEC.

Molina Healthcare's proxy statement outlines proposals for the 2025 annual meeting, including the approval of a new equity incentive plan and the election of directors, while also addressing executive compensation and corporate governance matters.

Molina Healthcare, Inc. has filed a definitive proxy statement with the SEC.

Molina Healthcare's proxy statement details proposals for the upcoming annual meeting, including director elections, executive compensation, and auditor ratification.

AQR Capital Management, through its subsidiaries, has reported beneficial ownership of 5.5% of Molina Healthcare's common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.19% of Molina Healthcare Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.37% in Molina Healthcare Inc. as of March 31, 2026.

T. Rowe Price Associates, Inc. has reported a 1.9% beneficial ownership stake in Molina Healthcare Inc. common stock as of December 31, 2025.

AQR Capital Management, LLC and its parent entity have disclosed a beneficial ownership of 0.8% of Molina Healthcare, Inc.'s common stock as of December 31, 2025.

FMR LLC and Abigail P. Johnson have reported a 5.8% beneficial ownership stake in Molina Healthcare Inc. as of December 31, 2025, held in the ordinary course of business.